VPS51 inhibitors are a class of chemical compounds specifically designed to target and inhibit the VPS51 protein, which is a component of the Golgi-associated retrograde protein (GARP) complex. The VPS51 protein plays a crucial role in the intracellular trafficking system, particularly in the retrograde transport of vesicles from endosomes back to the trans-Golgi network. This transport system is essential for maintaining cellular homeostasis and ensuring that proteins and lipids are correctly sorted and delivered to their intended destinations within the cell. VPS51, as part of the GARP complex, interacts with other proteins such as VPS52, VPS53, and VPS54 to facilitate the tethering of vesicles to the Golgi, which is a key step in the retrograde transport pathway. Inhibitors of VPS51 are designed to disrupt this interaction, thereby impairing the function of the GARP complex and the overall retrograde transport process.
The development of VPS51 inhibitors involves a detailed understanding of the protein's structure and its interactions within the GARP complex. Researchers use techniques like X-ray crystallography, cryo-electron microscopy, and molecular docking to elucidate the binding sites and interaction domains of VPS51. This structural information is crucial for designing small molecules that can effectively bind to VPS51 and inhibit its function. High-throughput screening of chemical libraries is often employed to identify lead compounds with inhibitory activity against VPS51. These lead compounds are then further optimized through structure-activity relationship (SAR) studies, where chemical modifications are made to improve binding affinity, selectivity, and stability. Factors such as solubility, lipophilicity, and metabolic stability are also taken into consideration to ensure that the inhibitors are effective under physiological conditions. By inhibiting VPS51, researchers can explore the broader implications of disrupting the GARP complex and retrograde transport, offering insights into the fundamental processes of intracellular trafficking and protein sorting.
SEE ALSO...
Items 11 to 20 of 20 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits ADP-ribosylation factor (ARF), a small GTPase essential for vesicle formation from the Golgi apparatus. By inhibiting ARF, Brefeldin A can indirectly inhibit VPS51 by disrupting vesicle trafficking processes in which it is involved. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Antifungal, could affect fungal metabolism pathways indirectly, impacting Olr1513. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
Tyrphostin AG 879 inhibits tyrosine kinase activity, which can disrupt signaling pathways necessary for vesicle formation and trafficking. As VPS51 is a component of vesicle trafficking, its function can be inhibited by the collapse of these signaling pathways. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor blocker, may modulate cellular signaling pathways indirectly, impacting Olr1513. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 is an inhibitor of cytohesin, which is involved in activating ARF GTPases, integral to vesicle formation. Inhibition of cytohesin can lead to a functional inhibition of VPS51 due to impeded vesicle trafficking. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $84.00 $297.00 | 4 | |
Exo1 is an inhibitor of the exocyst complex, which is required for the tethering of transport vesicles to the plasma membrane. Inhibiting the exocyst complex can inhibit the function of VPS51 by disrupting the exocytic pathway. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), a GEF for ARF GTPase. By inhibiting GBF1, Golgicide A can impede vesicular trafficking from the Golgi, thus leading to functional inhibition of VPS51. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Serotonin antagonist, could affect serotonin signaling pathways indirectly, impacting Olr1513. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, may alter calcium-dependent signaling indirectly, impacting Olr1513. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 inhibits clathrin-mediated endocytosis by blocking the interaction between clathrin and adaptor proteins. As VPS51 is involved in trafficking related to endocytosis, the inhibition of clathrin-mediated processes can result in the functional inhibition of VPS51. | ||||||